# US 2012/0231034 A1 · Use of botulinum neurotoxin to treat substance addictions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231034 A1
- Document ID: US20120231034A1
- Status: Published application
- Kind: A1
- Application number: 13/499,569
- Filed: 2010-09-30
- Published: 2012-09-13
- Earliest claimed: 2009-09-30
- Assignees: Toxcure, Inc.
- Inventors: Christopher Shaari
- Web page: https://patentgrep.com/patent/US20120231034A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61P 25/30: for treating abuse or dependence
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating a substance addiction- related behavior in a patient with a substance addiction, comprising the step of locally administering a therapeutically effective amount of a botulinum neurotoxin to a location on the patient's body or in the vicinity of the area which comes into contact with a smoking tool or addictive substance, thereby altering, reducing or eliminating sensations associated with behaviors associated with substance addiction. Botulinum neurotoxin may be administered to a dermal, subdermal, mucosal or submucosal location or to a muscle area or in the vicinity of the location to which a smoking tool or addictive substance contacts.

## Claims

### Claim 1

A method of treating substance addiction-related behaviors in a patient, comprising the step of locally administering a therapeutically effective dose of a botulinum neurotoxin to a location on the patient's body or in the vicinity of the location which comes into contact with a smoking tool or addictive substance.

### Claim 2 (depends on 1)

The method of claim 1, wherein the body location is inside of or around the opening of the mouth or nasal cavity of the patient or to a location on the hand or hands of the patient, thereby altering peripheral sensation of the body area.

### Claim 3 (depends on 2)

The method of claim 2, wherein the body location inside of the patient's mouth is the mucosal lining or salivary gland.

### Claim 4 (depends on 3)

The method of claim 3, wherein said therapeutically effective dose is sufficient to reduce mucosal/salivary secretions of the mouth, thereby having a drying effect on the mouth.

### Claim 5 (depends on 2)

The method of claim 2, wherein the body location around the opening of the patient's mouth is the lips or area immediately surrounding the lips.

### Claim 6 (depends on 5)

The method of claim 5, wherein the body location is within an about 1 cm2 area surrounding the patient's lips.

### Claim 7 (depends on 2)

The method of claim 2, wherein the body location is on a patient's hand or hands.

### Claim 8 (depends on 7)

The method of claim 7, wherein the hand location is selected from the group consisting of: thumb, index finger, middle finger, and a combination thereof.

### Claim 9 (depends on 2)

The method of claim 2, wherein the local administration of the botulinum neurotoxin is to a dermal, subdermal, mucosal or submucosal location or to a muscle with which a smoking tool or addictive substance contacts.

### Claim 10 (depends on 9)

The method of claim 9, wherein the local administration to the dermal location is by transdermal or transmucosal delivery.

### Claim 11 (depends on 10)

The method of claim 10, wherein the transdermal or transmucosal delivery is via a patch, cream, ointment or lotion vehicle comprising botulinum neurotoxin.

### Claim 12 (depends on 9)

The method of claim 9, wherein the local administration to the muscle is by intramuscular injection.

### Claim 13 (depends on 9, 10, 11, 12)

The method of any of claims 9-12, wherein said therapeutically effective dose is sufficient to alter the sensation of the dermal, subdermal, mucosal, submucosal or muscle location but less that a dose necessary to produce a substantial muscle weakness within the affected location.

### Claim 14 (depends on 2, 4)

The method of any one of claim 2 or 4, wherein the alteration in sensation or mucosal/salivary secretion persists for between about 1 month and about 6 months.

### Claim 15 (depends on 1)

The method of claim 1, wherein the smoking tool is selected from the group consisting of: a cigarette, a cigar, a pipe, a hookah, a bong and any tool from which tobacco, marijuana, cocaine and any addictive substance may be smoked.

### Claim 16 (depends on 1)

The method of claim 1, wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin serotype A, B, C, D, E, F and G.

### Claim 17 (depends on 16)

The method of claim 16, wherein the botulinum neurotoxin is botulinum neurotoxin serotype A.

### Claim 18 (depends on 16)

The method of claim 16, wherein the botulinum neurotoxin is botulinum neurotoxin serotype B.

### Claim 19 (depends on 17)

The method of claim 17, wherein the botulinum neurotoxin is administered in an amount of between about 0.25 unit and about 1,500 units of serotype A toxin, such that a therapeutically effective amount acts on the neurons or muscles of interest to induce a change in substance addiction-related behavior.

### Claim 20 (depends on 18)

The method of claim 18, wherein the botulinum neurotoxin is administered in an amount of 1 unit and 50,000 units of serotype B toxin, such that a therapeutically effective amount acts on the neurons or muscles of interest to induce a change in substance addiction-related behavior.
